The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Insulet Corporation (“Insulet” or the “Company”) (NASDAQ:PODD) securities during the period of February 21, 2025 through May 26, 2026, inclusive (“the Class Period”).
If you suffered a loss on your Insulet investments, you have until August 31, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. If you choose to take no action, you may remain an absent class member. For more information about the lawsuit:
[CONTACT THE FIRM IF YOU SUFFERED A LOSS]
What Is This Lawsuit About? The lawsuit alleges that throughout the Class Period, Insulet made public statements that were misleading for failure to disclose that: (i) Insulet’s manufacturing controls and procedures were defective and (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury.
On March 12, 2026, Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” On this news, the price of Insulet shares declined by $16.23 per share, or approximately 7%, from $236.07 per share on March 12, 2026 to close at $219.84 on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the “initiation” of another “voluntary Medical Device Correction”, this time “for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.” On this news, the price of Insulet shares declined by $7.79 per share, or approximately 5%, from $153.80 per share on May 26, 2026 to close at $146.01 on May 27, 2026.
[LEARN MORE ABOUT THE LAWSUIT]
The Lead Plaintiff Appointment Process. The federal securities laws permit any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in a class action lawsuit. Learn more about the lead plaintiff process and eligibility requirements here. Courts typically appoint the investor(s) with the largest financial loss in the case and the ability to represent the class rather than investors with simply the largest investment portfolio. Courts regularly appoint individual investors, whether acting alone or as a group, as lead plaintiffs. The rights of any investor who bought shares during the class period are generally already protected. However, lead plaintiffs have the power to influence case strategy and have a say in settlement decisions, as well as decisions concerning allocation of settlement funds among class members.
[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS]
What Should I Do? If you purchased or otherwise acquired Insulet securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260706166556/en/
Media gallery
